Suggested remit - To appraise the clinical and cost effectiveness of brigatinib within its marketing authorisation for untreated ALK-positive metastatic non-small-cell lung cancer.
 
Status In progress
Process STA 2018
ID number 1468

Provisional Schedule

Expected publication 14 October 2020

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
13 June 2019 As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of brigatinib for untreated ALK-positive metastatic non-small-cell lung cancer. Please note that following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late -November 2019. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust evidence submission.
25 January 2019 As you will be aware, the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of brigatinib for untreated ALK-positive metastatic non-small-cell lung cancer. Please note that following on from advice received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-August 2019.
02 October 2018 - 30 October 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators
18 April 2018 In progress, Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance